Moderna
Stock Forecast, Prediction & Price Target
Moderna (MRNA) stock Price Target by analysts
$92.9
Potential upside: 234.77%
Moderna price prediction

What is Moderna stock analysts` prediction?
Moderna stock forecast: Based on 8 Wall Street analysts` predicted price targets for Moderna in the last 3 months, the avarage price target is $92.9, with a high forecast of $NaN. The average price target represents a 234.77% change from the last price of $27.75.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Moderna stock Price Target by analysts
Full breakdown of analysts given Moderna price targets
Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
---|---|---|---|---|---|---|
Edward Tenthoff Piper Sandler | 0% 0/5 | 10 months ago | $69 148.64% upside | $37.27 | StreetInsider | Previous targets (4) |
Yifeng Liu HSBC | 0% 0/2 | 10 months ago | $58 109.00% upside | $84.93 | StreetInsider | Previous targets (1) |
Courtney Breen Bernstein | 0% 0/1 | 11 months ago | $55 98.19% upside | $57.46 | TheFly | Previous targets (0) |
Michael Yee Jefferies | 33.33% 2/6 | 11 months ago | $55 98.19% upside | $57.73 | TheFly | Previous targets (5) |
Edward Tenthoff Piper Sandler | 0% 0/5 | 12 months ago | $115 314.41% upside | $69.68 | StreetInsider | Previous targets (4) |
Luca Issi RBC Capital | 0% 0/4 | 12 months ago | $75 170.27% upside | $69.68 | StreetInsider | Previous targets (3) |
Leah Rush Cann Loop Capital Markets | 0% 0/2 | 12 months ago | $238 757.65% upside | $69.68 | StreetInsider | Previous targets (1) |
Matthew Harrison Morgan Stanley | 50% 3/6 | 12 months ago | $94 238.73% upside | $67.51 | StreetInsider | Previous targets (5) |
Michael Yee Jefferies | 33.33% 2/6 | 12 months ago | $65 134.23% upside | $69.68 | TheFly | Previous targets (5) |
Cory Kasimov Evercore ISI | 0% 0/2 | 12 months ago | $105 278.37% upside | $67.68 | StreetInsider | Previous targets (1) |
Peter Arment Robert W. Baird | 0% 0/1 | about 1 year ago | $220 692.79% upside | $78.52 | Benzinga | Previous targets (0) |
Yifeng Liu HSBC | 0% 0/2 | about 1 year ago | $82 195.49% upside | $78.98 | TheFly | Previous targets (1) |
Emmanuel Papadakis Deutsche Bank | 25% 1/4 | about 1 year ago | $80 188.28% upside | $82.3 | TheFly | Previous targets (3) |
Luca Issi RBC Capital | 0% 0/4 | about 1 year ago | $90 224.32% upside | $86.58 | TheFly | Previous targets (3) |
Edward Tenthoff Piper Sandler | 0% 0/5 | about 1 year ago | $157 465.76% upside | $90.03 | TheFly | Previous targets (4) |
Hartaj Singh Oppenheimer | 0% 0/3 | about 1 year ago | $179 545.04% upside | $148.39 | TheFly | Previous targets (2) |
Leah Rush Cann Loop Capital Markets | 0% 0/2 | about 1 year ago | $310 1017.11% upside | $147.47 | StreetInsider | Previous targets (1) |
Michael Yee Jefferies | 33.33% 2/6 | about 1 year ago | $180 548.64% upside | $152.03 | TheFly | Previous targets (5) |
Luca Issi RBC Capital | 0% 0/4 | over 1 year ago | $160 476.57% upside | $141.83 | TheFly | Previous targets (3) |
Cory Kasimov Evercore ISI | 0% 0/2 | over 1 year ago | $120 332.43% upside | $125.67 | StreetInsider | Previous targets (1) |
Emmanuel Papadakis Deutsche Bank | 25% 1/4 | over 1 year ago | $85 206.30% upside | $124.06 | TheFly | Previous targets (3) |
Eliana Merle UBS | 0% 0/4 | over 1 year ago | $151 444.14% upside | $122.13 | TheFly | Previous targets (3) |
Bill Maughan Canaccord Genuity | 50% 1/2 | over 1 year ago | $106 281.98% upside | $125.59 | TheFly | Previous targets (1) |
Michael Yee Jefferies | 33.33% 2/6 | over 1 year ago | $155 458.55% upside | $123.02 | TheFly | Previous targets (5) |
Hartaj Singh Oppenheimer | 0% 0/3 | over 1 year ago | $163 487.38% upside | $125.59 | StreetInsider | Previous targets (2) |
Luca Issi RBC Capital | 0% 0/4 | over 1 year ago | $135 386.48% upside | $125.59 | StreetInsider | Previous targets (3) |
Matthew Harrison Morgan Stanley | 50% 3/6 | over 1 year ago | $95 242.34% upside | $125 | StreetInsider | Previous targets (5) |
Matthew Harrison Morgan Stanley | 50% 3/6 | over 1 year ago | $89 220.72% upside | $108.85 | StreetInsider | Previous targets (5) |
Michael Yee Jefferies | 33.33% 2/6 | over 1 year ago | $125 350.45% upside | $110.59 | StreetInsider | Previous targets (5) |
Eliana Merle UBS | 0% 0/4 | over 1 year ago | $143 415.31% upside | $107.41 | StreetInsider | Previous targets (3) |
Bill Maughan Canaccord Genuity | 50% 1/2 | over 1 year ago | $82 195.49% upside | $87.59 | Benzinga | Previous targets (1) |
Matthew Harrison Morgan Stanley | 50% 3/6 | over 1 year ago | $123 343.24% upside | $87.59 | Benzinga | Previous targets (5) |
Hartaj Singh Oppenheimer | 0% 0/3 | over 1 year ago | $142 411.71% upside | $113.15 | Benzinga | Previous targets (2) |
Eliana Merle UBS | 0% 0/4 | about 2 years ago | $191 588.28% upside | $121.14 | Benzinga | Previous targets (3) |
Unknown Piper Sandler | N/A | over 2 years ago | $217 681.98% upside | $189.89 | Benzinga | N/A |
Unknown Jefferies | N/A | over 2 years ago | $275 890.99% upside | $193.29 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 2 years ago | $209 653.15% upside | $191.78 | Benzinga | N/A |
Unknown Chardan Capital | N/A | over 2 years ago | $191 588.28% upside | $212.41 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 2 years ago | $102 267.56% upside | $197.54 | Benzinga | N/A |
Jasper Hellweg Hellweg Argus Research | 100% 1/1 | almost 3 years ago | $150 440.54% upside | $123.64 | Pulse 2.0 | Previous targets (0) |
Edward Tenthoff Piper Sandler | 0% 0/5 | over 3 years ago | $214 671.17% upside | $142.28 | TheFly | Previous targets (4) |
Matthew Harrison Morgan Stanley | 50% 3/6 | over 3 years ago | $199 617.11% upside | $155.05 | Pulse 2.0 | Previous targets (5) |
Edward Tenthoff Piper Sandler | 0% 0/5 | over 3 years ago | $348 1154.05% upside | $176.59 | Pulse 2.0 | Previous targets (4) |
Matthew Harrison Morgan Stanley | 50% 3/6 | over 3 years ago | $205 638.73% upside | $173.08 | Pulse 2.0 | Previous targets (5) |
Emmanuel Papadakis Deutsche Bank | 25% 1/4 | over 3 years ago | $155 458.55% upside | $129.28 | Pulse 2.0 | Previous targets (3) |
Michael Yee Jefferies | 33.33% 2/6 | over 3 years ago | $170 512.61% upside | $151.33 | Pulse 2.0 | Previous targets (5) |
Gena Wang Barclays | 0% 0/1 | over 3 years ago | $210 656.75% upside | $156.23 | TipRanks Contributor | Previous targets (0) |
Tyler Van Buren Cowen & Co. | 100% 1/1 | over 3 years ago | $200 620.72% upside | $172.74 | Pulse 2.0 | Previous targets (0) |
Emmanuel Papadakis Deutsche Bank | 25% 1/4 | over 3 years ago | $175 530.63% upside | $154.96 | Pulse 2.0 | Previous targets (3) |
Eliana Merle UBS | 0% 0/4 | over 3 years ago | $221 696.39% upside | $160.07 | TheFly | Previous targets (3) |
Moderna Financial Estimates
Moderna Revenue Estimates
Moderna EBITDA Estimates
Moderna Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $17.73B N/A | $19.26B 8.60% | $6.84B -64.44% | Avg: $4.80B Low: $3.85B High: $6.76B avg. -29.77% | Avg: $6.55B Low: $5.49B High: $8.03B avg. 36.29% | Avg: $9.03B Low: $7.57B High: $11.06B avg. 37.81% | Avg: $12.45B Low: $10.44B High: $15.26B avg. 37.92% |
Net Income
% change YoY
| $12.20B N/A | $8.36B -31.47% | $-4.71B -156.37% | Avg: $-2.05B Low: $-2.74B High: $-378.18M avg. 56.42% | Avg: $-482.39M Low: $-2.31B High: $4.95B avg. 76.51% | Avg: $926.29M Low: $731.61M High: $1.19B avg. 292.02% | Avg: $3.05B Low: $2.41B High: $3.94B avg. 229.82% |
EBITDA
% change YoY
| $13.29B N/A | $9.76B -26.53% | $-3.28B -133.60% | Avg: $-1.17B Low: $-1.64B High: $-938.59M avg. 64.29% | Avg: $-1.59B Low: $-1.95B High: $-1.33B avg. -36.29% | Avg: $-2.20B Low: $-2.69B High: $-1.84B avg. -37.81% | Avg: $-3.03B Low: $-3.72B High: $-2.54B avg. -37.92% |
EPS
% change YoY
| $30.28 N/A | $21.22 -29.92% | -$12.34 -158.15% | Avg: -$5.26 Low: -$7.19 High: -$0.99 avg. 57.39% | Avg: -$1.65 Low: -$6.05 High: $12.97 avg. 68.70% | Avg: $2.42 Low: $1.92 High: $3.13 avg. 247.36% | Avg: $8 Low: $6.32 High: $10.34 avg. 229.82% |
Operating Expenses
% change YoY
| $1.82B N/A | $4.42B 142.84% | $6.39B 44.43% | Avg: $3.16B Low: $2.53B High: $4.44B avg. -50.54% | Avg: $4.31B Low: $3.61B High: $5.28B avg. 36.29% | Avg: $5.93B Low: $4.97B High: $7.27B avg. 37.81% | Avg: $8.19B Low: $6.86B High: $10.03B avg. 37.92% |
FAQ
What is Moderna stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 163.69% in 2025-2028.
We have gathered data from 18 analysts. Their low estimate is -2.74B, average is -2.05B and high is -378.18M.
What is Moderna stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 20.56% in 2025-2028.
We have gathered data from 18 analysts. Their low revenue estimate is $3.85B, average is $4.80B and high is $6.76B.
What is Moderna stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 150.81% in 2025-2028.
We have gathered data from 18 analysts. Their low earnings per share estimate is -$7.19, average is -$5.26 and high is $-0.99.
What is the best performing analyst?
In the last twelve months 8 analysts have been covering Moderna stock. The most successful analyst is Edward Tenthoff.